Why the study?
Surgically implanted bioprostheses increasingly require re-intervention for structural valve deterioration, but ViV TAVR poses challenges including higher rates of prosthesis-patient mismatch and coronary obstruction compared to native valve TAVR.
Design
State-of-the-art review
Key result
Valve-in-valve TAVR serves as an alternative to reoperative surgery for high-risk patients with structural valve deterioration, despite higher risks of prosthesis-patient mismatch and coronary obstruction.
Authors
Loading...
Demands individualized risk assessment before use; leaves open need for randomized comparisons to reoperative surgery.
Valve-in-valve TAVR serves as an alternative to reoperative surgery for high-risk patients with structural valve deterioration, though it carries specific procedural challenges.
Edelman et al. (2019) conducted a review in Structural valve deterioration of surgically implanted bioprostheses. Valve-in-valve transcatheter aortic valve replacement (ViV TAVR) vs. Reoperative surgery / Native valve TAVR was evaluated. Valve-in-valve TAVR serves as an alternative to reoperative surgery for high-risk patients with structural valve deterioration, despite higher risks of prosthesis-patient mismatch and coronary obstruction.